Keyphrases
Traumatic Brain Injury
54%
Alzheimer's Disease
36%
Mild Cognitive Impairment
35%
Injury History
30%
Montreal Cognitive Assessment (MoCA)
29%
Assessment Score
23%
Age of Diagnosis
18%
Age of Onset
15%
Loss of Consciousness
11%
Psychosocial Outcomes
10%
National Football League
9%
Retirees
9%
Community-based Sample
9%
Injury Progression
9%
Scoping Review
9%
Race-ethnicity
9%
Telomere Length
9%
Luria Test
9%
Three-step Test
9%
Luria
9%
Postconcussive
9%
High School Athletes
9%
Regional Brain Volumes
9%
Predictors of Cognitive Decline
9%
Word Properties
9%
Choctaw
9%
Randomized Controlled Trial
9%
Dementia Risk Reduction
9%
Professional Athletes
9%
Cognitive Ability
9%
Cognitive Impact
9%
Subclinical Atherosclerosis
9%
Actuarial Method
9%
Noise Regression
9%
Dementia Onset
9%
Irregular Bodies
9%
Psychological Symptoms
9%
Cognitive Function
9%
Middle School
9%
Concussion Recovery
9%
Aerobic Training
9%
Exercise Training
9%
Early Age of Onset
9%
Traumatic Encephalopathy Syndrome
9%
Autopsy-confirmed
9%
Post-concussion Syndrome
9%
Amnestic Mild Cognitive Impairment (aMCI)
9%
Recovery Time
9%
Phone Contacts
9%
Medically Compromised Patients
9%
Psychology
Alzheimer's Disease
100%
Mild Cognitive Impairment
77%
Traumatic Brain Injury
63%
Montreal Cognitive Assessment
58%
Consciousness
28%
Adolescents
27%
Cognitive Impairment
23%
Analysis of Variance
12%
Regression Model
12%
Cognitive Function
12%
Sex Education
11%
Cognitive Decline
10%
Beck Depression Inventory
9%
Resting-State
9%
Resting-State fMRI
9%
Scoping Review
9%
Neuroimaging
9%
Functional Magnetic Resonance Imaging
9%
Critical Review
9%
Clinical Interview
9%
Sex Differences
9%
Mental State
8%
Analysis of Covariance
7%
Cognitive Functioning
7%
Rating Scale
6%
Medicine and Dentistry
Alzheimer's Disease
61%
Traumatic Brain Injury
27%
Risk Reduction
22%
Clinical Trial
20%
Onset Age
18%
Life Expectancy
18%
Cognition
11%
Post-Hoc Analysis
9%
Functional Magnetic Resonance Imaging
9%
Patient Referral
9%
Microangiopathy
9%
Resting State fMRI
9%
Independent Component Analysis
9%
Atherosclerosis
9%
Urinary System
9%
Creatinine
9%
Frontotemporal Lobar Degeneration
9%
Biological Marker
9%
Montreal Cognitive Assessment
9%
4 Iodo 2,5 Dimethoxyamphetamine
9%
Symptom
7%
Loss of Consciousness
7%
Frontal Variant Frontotemporal Dementia
6%
Cognitive Defect
6%
